Analyst firms · B. Riley Securities · MDGL
B. Riley Securities MDGL price target and rating history
Madrigal Pharmaceuticals Inc. (MDGL) · Health Care
B. Riley Securities rates Madrigal Pharmaceuticals Inc. (MDGL) Buy with a $422 price target, as of its latest action on Feb 28, 2025. It has published 4 rating actions on MDGL since July 2022, including 2 upgrades and 2 downgrades. Across 5 firms with a MDGL price target in the last 12 months, the median target is $704.
- Current rating
- Buy
- Price target
- $422
- Median target, all firms
- $704
- Actions on MDGL
- 4
B. Riley Securities price target on MDGL
Every B. Riley Securities rating on MDGL
- Feb 28, 2025
- Mar 15, 2024
- Feb 26, 2024
- Jul 8, 2022
How other firms rate MDGL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $704 | Sep 24, 2026 |
| Citigroup | Buy | $725 | Sep 23, 2026 |
| Wolfe Research | Outperform | $605 | Aug 4, 2026 |
| Wells Fargo | Overweight | $685 | Jul 27, 2026 |
| Barclays | Overweight | $964 | Jan 28, 2026 |
Questions about B. Riley Securities and MDGL
- What is B. Riley Securities's price target for MDGL?
- B. Riley Securities's latest stated price target for Madrigal Pharmaceuticals Inc. (MDGL) is $422, from its action on Feb 28, 2025.
- What is B. Riley Securities's rating on MDGL?
- B. Riley Securities rates MDGL Buy, a bullish rating, as of Feb 28, 2025.
- When did B. Riley Securities last change its view on MDGL?
- On Feb 28, 2025, B. Riley Securities upgrades to Buy from Neutral, price target $236 to $422.
- How does B. Riley Securities's MDGL target compare with other analysts?
- Across 5 firms with a MDGL price target in the last 12 months, the median target is $704.
More MDGL rating histories
All B. Riley Securities ratingsMDGL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.